BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17728330)

  • 1. Granuloma annulare induced by anti-tumour necrosis factor therapy.
    Voulgari PV; Markatseli TE; Exarchou SA; Zioga A; Drosos AA
    Ann Rheum Dis; 2008 Apr; 67(4):567-70. PubMed ID: 17728330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
    Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
    Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
    Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
    Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
    J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2007 Apr; 46(4):695-8. PubMed ID: 17158212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases].
    Benucci M; Nenci G; Cappelletti C; Manfredi M
    Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
    Stokes MB; Foster K; Markowitz GS; Ebrahimi F; Hines W; Kaufman D; Moore B; Wolde D; D'Agati VD
    Nephrol Dial Transplant; 2005 Jul; 20(7):1400-6. PubMed ID: 15840673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents.
    Popa C; Barrera P; Joosten LA; van Riel PL; Kullberg BJ; van der Meer JW; Netea MG
    Eur Cytokine Netw; 2009 Jun; 20(2):88-93. PubMed ID: 19541595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.
    Marchesoni A; Zaccara E; Gorla R; Bazzani C; Sarzi-Puttini P; Atzeni F; Caporali R; Bobbio-Pallavicini F; Favalli EG
    Ann N Y Acad Sci; 2009 Sep; 1173():837-46. PubMed ID: 19758236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
    Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
    Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.